Stroke prevention in atrial fibrillation: Impact of novel oral anticoagulants

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 3, 2013, Pages 241-248

  Haft, Jacob I ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

administration; anticoagulants; atrial fibrillation; oral; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; ATECEGATRAN METOXIL; BETRIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; WARFARIN;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; EMBOLISM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW;

ADMINISTRATION; ANTICOAGULANTS; ATRIAL FIBRILLATION; ORAL; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; FACTOR XA; HUMANS; STROKE; VITAMIN K;

EID: 84878845081     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612458148     Document Type: Review

References (53)

1. Weiss S, Davis D. Rheumatic heart disease III. Embolic manifestations. Am Heart J. 1933 ; 9: 45-52
2. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978 ; 28 (10). 973-977
3. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ. 2002 ; 325 (7371). 1022-1025
4. Go AS, Hylek EM, Phillips KA. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 ; 285 (18). 2370-2375
5. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J. 1964 ; 1 (5392). 1209-1212
6. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999 ; 9 (4). 215-217
7. Harenberg J. New anticoagulants in atrial fibrillation. Semin Thromb Hemost. 2009 ; 35 (6). 574-585
8. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008 ; 133 (6 suppl). 546S - 592S
9. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008 ; 133 (6 suppl). 160S - 198S
10. United States Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [press release]. http://www.fda.gov.NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. October 19, 2010.
11. Janssen. XARELTO® (Rivaroxaban) prescribing information. 2011.
12. Bristol-Myers Squibb, Pfizer EEIG. Eliquis® (Apixaban) summary of product characteristics. 2011.
13. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 ; 146 (12). 857-867
14. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141 (2 suppl). e531S - e575S
15. Amouyel P, Mismetti P, Langkilde LK, Jasso-Mosqueda G, Nelander K, Lamarque H. INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med. 2009 ; 20 (1). 63-69
16. Connolly S, Pogue J, Hart R. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 ; 367 (9526). 1903-1912
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 ; 137 (2). 263-272
18. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008 ; 39 (6). 1901-1910
19. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke. 2007 ; 38 (11). 2935-2940
20. Haft JI. Echocardiographic findings that may help identify occult intermittent atrial fibrillation in hypertensive patients at risk for a second (or first) ischemic stroke. Stroke. 2008 ; 39 (6). e91
21. Haft JI, Teichholz LE. Echocardiographic and clinical risk factors for atrial fibrillation in hypertensive patients with ischemic stroke. Am J Cardiol. 2008 ; 102 (10). 1348-1351
22. Haft JI. The importance of atrial fibrillation/flutter as a cause of ischemic stroke. Int J Cardiol. 2012 ; 158 (1). 143-144
23. Haft JI. Atrial fibrillation is the mechanism for stroke in patients with the risk factors for stroke. Abstract P1-6. Presented at: the 11th International Dead Sea Symposium on Cardiac Arrhythmias and Device Therapy ; Jerusalem, Israel ;.
24. Ziegler PD, Glotzer TV, Daoud EG. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke. 2010 ; 41 (2). 256-260
25. Weitz JI. New oral anticoagulants in development. Thromb Haemost. 2010 ; 103 (1). 62-70
26. Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag. 2008 ; 4 (6). 1373-1386
27. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009 ; 48 (1). 1-22
28. Cullberg M, Wåhlander K, Jansson S, et al. Safety, pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor AZD0837 in young healthy volunteers. Basic Clin Pharmacol Toxicol. 2007 ; 101: 130
29. Lip GY, Rasmussen LH, Olsson SB. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009 ; 30 (23). 2897-2907
30. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009 ; 101 (1). 68-76
31. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 (12). 1139-1151
32. Patel MR. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010 ; 159 (3). 340-347
33. Eikelboom JW, O'Donnell M, Yusuf S. Rationale and design of AVERROES: Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010 ; 159 (3). 348-353
34. Lopes RD, Alexander JH, Al Khatib SM. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010 ; 159 (3). 331-339
35. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 ; 154 (1). 1-11
36. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011 ; 123 (22). 2562-2570
37. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011 ; 105 (5). 908-919
38. Adcock AK, Lee-Iannotti JK, Aguilar MI, et al. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic. Neurologist. 2012 ; 18 (2). 102-107
39. Ali A, Bailey C, Abdelhafiz AH. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis [published online February 28, 2012]. Age Ageing. 2012 ;:
40. RELY-ABLE long term multi-center extension of dabigatran treatment in patients with artial fibrillation who completed RE-LY trials. Clinicaltrials.gov.:
41. Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 (10). 883-891
42. Connolly SJ, Eikelboom J, Joyner C. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 ; 364 (9). 806-817
43. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 (11). 981-992
44. Bristol-Myers Squibb. AVERROES: Averroes study of investigational agent apixaban closes early due to clear evidence of efficacy. http://media.pfizer. com/files/news/press-releases/2010/averroes-apixaban-061010.pdf
45. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. J Med Econ. 2012 ; 15 (4). 776-785
46. Ruff CT, Giugliano RP, Antman EM. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor x. A next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010 ; 160 (4). 635-641
47. Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin (EXPLORE-Xa). 2011 ;:
48. Eriksson BI, Turpie AG, Lassen MR. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost. 2007 ; 5 (8). 1660-1665
49. Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res. 2011 ; 127 (6). 497-504
50. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology. 2011 ; 43 (7). 682-692
51. Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med. 2011 ; 12 (4). 386-392
52. Battinelli EM. Reversal of new oral anticoagulants. Circulation. 2011 ; 124 (14). 1508-1510
53. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011 ; 124 (14). 1573-1579